Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Thermo Fisher Scientific Introduces New Quaternary Pump
The new Thermo Scientific Accela 1250 pump features Force Feedback Control (FFC) which eliminates the need for pulse dampening while improving flow accuracy and gradient precision under extreme
The new Thermo Scientific Accela 1250 pump features Force Feedback Control (FFC) which eliminates the need for pulse dampening while improving flow accuracy and gradient precision under extreme
The audit was performed as part of the Ministry of Health’s evaluation of Protalix’s manufacturing process of taliglucerase alfa for the treatment of Gaucher disease. Earlier, in February
BioVex said that the Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in
Lanxess will invest about EUR50m in total at the 13 hectare Jhagadia site, which will include a rubber chemicals plant and a new ion exchange resins plant. This
CancerTYPE ID is a diagnostic test which predicts cancer origin in patients whose primary cancer was initially ‘unknown or uncertain’ using conventional diagnostics. Knowing the site where the
Intas intends to launch a double-blind, placebo-controlled Phase 3 clinical trial of ABI’s orally administered interferon-alpha lozenges in India before the end of March. The study will involve
Humacyte’s vascular graft is based on its proprietary platform technology for engineering human, extracellular matrix-based tissues having properties analogous to native tissues. The company’s vascular grafts will first
FDA determined that Vyvanse qualified as an NCE within the meaning of the governing statutes and regulations. As an NCE, Vyvanse is entidtled to 5-year market exclusivity. The
Scientists at Kyto have isolated and cloned the Transcobalamin Receptor which has been shown to be over expressed in various forms of cancer. The primary therapeutic approach developed
Health Sciences International, based in Connecticut, aims to conduct quality phase I-IV trial research with key therapeutic areas of focus including cardiology, vascular disorders, CNS, endocrinology and internal